What is Dasatinib?

Dasatinib (Dasatinib) is an oral multikinase inhibitor used to treat Philadelphia chromosome (Ph)-positive leukemia. Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL), in which the ABL tyrosine kinase and breakpoint cluster region (BCR) genes transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with uncontrolled activity of the ABL tyrosine kinase and is implicated in the pathogenesis of CML and 15-30% of all cases.

Dasatinib also inhibits a range of cancer-related kinases, including severalSRC family kinases. Unlike imatinib, another tyrosine kinase used to treat CML and Ph-positive ALL, dasatinib inhibits both active and inactive conformations of the ABL kinase domain. In addition, mutations in the BCR-ABL kinase domain may contribute to relapse during imatinib treatment. Because dasatinib does not interact with some of the residues involved in these mutations, use of the drug represents a treatment alternative for patients with imatinib-resistant cancers.

The original drug of dasatinib has been launched in China and is included in the medical insurance. Currently, reimbursement is only available to eligible patients. Common specifications The price of each box of 50mg*60 tablets may be around RMB 10,000. The original drug overseas is even more expensive. Dasatinib generics are also sold overseas. The ingredients of the drug are basically the same as those sold domestically and abroad, but the price is cheap. For example, the price of a box of 50mg*60 tablets produced by an Indian pharmaceutical factory may be several hundred yuan (the price may fluctuate due to exchange rates).